HAVCR2 and metabolic dysfunction-associated steatohepatitis: Our study showed that macrophage TIM3 knockdown or antibody blockade attenuated NASH-associated liver fibrosis in mice, providing a possible basis for immunotherapy of liver fibrosis (Fig. 8).